Results 221 to 230 of about 28,689 (318)

Revised "iRR6" model in intermediate-1 risk myelofibrosis patients treated with ruxolitinib. [PDF]

Cancer
Palandri F, Branzanti F, Bonifacio M, Elli EM, Morsia E, Farina M, Tiribelli M, Benevolo G, Beggiato E, Martino B, Caocci G, Pugliese N, Tieghi A, Crugnola M, Binotto G, Cavazzini F, Abruzzese E, Isidori A, Dedola A, Scalzulli E, Duminuco A, Tosoni L, Strazimiri A, Lemoli RM, Cilloni D, Bocchia M, Pane F, Sartor C, Heidel FH, Breccia M, Palumbo GA, Kuykendall AT.   +31 more
europepmc   +1 more source

Markers of iron deficiency in patients with polycythemia vera receiving ruxolitinib or best available therapy

, 2017
Srđan Verstovšek, Claire Harrison, Jean‐Jacques Kiladjian, Carole B. Miller, Ahmad Naim, Dilan Paranagama, Dany Habr, Alessandro M. Vannucchi   +7 more
openalex   +1 more source

Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial [PDF]

, 2018
Martin Grießhammer, Güray Saydam, Francesca Palandri, Giulia Benevolo, Miklós Egyed, Jeannie Callum, Timothy Devos, Serdar Şıvgın, Paola Guglielmelli, Caroline Bensasson, Md Mahmudul Hasan Khan, Julian Perez Ronco, Francesco Passamonti   +12 more
openalex   +1 more source

Lichenoid graft‐versus‐host disease shows a high interferon score, with IFNAR1 inhibition preventing skin inflammation

Journal of the European Academy of Dermatology and Venereology, Volume 39, Issue 10, Page 1832-1843, October 2025.
This study identifies interferons as key mediators in lichenoid chronic GVHD pathogenesis, along with Th2 and Th17 involvement. It particularly highlights the role of Type I interferon, showing that early anti‐IFNAR1 treatment reduces skin inflammation in a murine model of chronic cutaneous GVHD.
Chloé Grolleau, Thomas Poisot, Andreea Calugareanu, Regis Peffault De Latour, Marie Robin, David Michonneau, Flore Sicre de Fontbrune, Adèle de Masson, Maxime Battistella, Gerard Socié, Hélène Le Buanec, Jean‐David Bouaziz   +11 more
wiley   +1 more source

Revisiting Janus Kinase Inhibitors in Hospitalized COVID-19: Evidence for Baricitinib's Superiority and the Absence of a Class Effect. [PDF]

J Inflamm Res
Gu L, Lin J, Yue J, Liu Z, Huang JA.
europepmc   +1 more source

A Scoping Review of Pathogenesis, Current Treatments, and Novel Approaches for Vitiligo

Journal of Cosmetic Dermatology, Volume 24, Issue 10, October 2025.
ABSTRACT Background Vitiligo is a chronic skin disorder characterized by loss of melanocytes, causing depigmentation and psychological distress. Its pathogenesis is complex and multifactorial, involving genetic predisposition, autoimmune, oxidative stress, and neurogenic mechanisms.
Nusaibah Sallehuddin, Nur Izzah Md Fadilah, Mh Busra Fauzi, Manira Maarof   +3 more
wiley   +1 more source

Remestemcel-L-rknd (Ryoncil): the first approved cellular therapy for steroid-refractory acute GVHD. [PDF]

Blood
Etra A, Ferrara JLM, Levine JE.
europepmc   +1 more source

Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease [PDF]

, 2018
H. Jean Khoury, Amelia Langston, Vamsi Kota, Jennifer A. Wilkinson, Iskra Pusic, Anand Jillella, Stephanie Bauer, Audrey S Kim, Danielle Roberts, Zaid Al‐Kadhimi, Imre Bodó, Elliott F. Winton, Martha Arellano, John F. DiPersio   +13 more
openalex   +1 more source

A case‐based discussion of clinical problems in the management of patients treated with ruxolitinib for myelofibrosis

, 2017
P. Joy Ho, Ashish Bajel, Kate Burbury, Lindsay Dunlop, Simon Durrant, Cecily Forsyth, Andrew C. Perkins, David M. Ross   +7 more
openalex   +2 more sources

Dramatic response of refractory sarcoidosis under ruxolitinib in a patient with associated JAK2-mutated polycythemia [PDF]

, 2018
Cécile Rotenberg, Valérie Besnard, Pierre‐Yves Brillet, Stéphane Giraudier, Hilario Nunès, Dominique Valeyre   +5 more
openalex   +1 more source